Invention Grant
US08481030B2 Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
有权
针对组织因子途径抑制剂（TFPI）的优化单克隆抗体
- Patent Title: Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
- Patent Title (中): 针对组织因子途径抑制剂（TFPI）的优化单克隆抗体
-
Application No.: US13323691Application Date: 2011-12-12
-
Publication No.: US08481030B2Publication Date: 2013-07-09
- Inventor: Zhuozhi Wang , Junliang Pan , Joanna Grudzinska , Christian Votsmeier , Jan Tebbe , Joerg Birkenfeld , Nina Wobst , Simone Brueckner , Susanne Steinig , Peter Scholz
- Applicant: Zhuozhi Wang , Junliang Pan , Joanna Grudzinska , Christian Votsmeier , Jan Tebbe , Joerg Birkenfeld , Nina Wobst , Simone Brueckner , Susanne Steinig , Peter Scholz
- Applicant Address: US NY Tarrytown
- Assignee: Bayer Healthcare LLC
- Current Assignee: Bayer Healthcare LLC
- Current Assignee Address: US NY Tarrytown
- Agency: Orrick, Herrington & Sutcliffe LLP
- Main IPC: A61K39/395
- IPC: A61K39/395
Abstract:
Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) are provided. Isolated nucleic acid molecules encoding monoclonal antibodies that bind TFPI are also contemplated. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided.
Public/Granted literature
- US20120108796A1 Optimized Monoclonal Antibodies against Tissue Factor Pathway Inhibitor (TFPI) Public/Granted day:2012-05-03
Information query
